P.I. Industries eyes H2FY27 export recovery amid CSM headwinds and pharma scale-up

Investment View and Target Price

In its August 12, 2026 Q1FY27 result update, Prabhudas Lilladher maintained its HOLD rating on P.I. Industries and reduced its target price to Rs2,569 from Rs2,792. The report was prepared by Saurabh Ahire, Swarnendu Bhushan and Tejas Kadam.

The broker expects near-term agrochemical-sector challenges to weigh on performance, particularly soft commodity prices, genericisation pressure in global agrochemicals and P.I. Industries' exposure to pyroxasulfone after its patent expiry. PL nevertheless expects a recovery in biologicals and the scaling up of the pharma business to support medium-term growth.

Q1FY27 Financial Performance

P.I. Industries reported consolidated Q1FY27 revenue of Rs17,023 million, down 10.4 per cent year on year but up 8.8 per cent quarter on quarter. Revenue was 2.2 per cent above PL's estimate of Rs16,649 million but below consensus of Rs17.6 billion.

Gross margin declined to 56.7 per cent from 57.4 per cent in Q1FY26 and 57.8 per cent in Q4FY26. EBITDA was 4.3 per cent below PL's estimate, while reported PAT was 9.4 per cent below the broker's estimate of Rs2,694 million.

CSM Business and Export Recovery

Custom Synthesis and Manufacturing, or CSM, accounted for 76 per cent of Q1FY27 revenue and declined 12.7 per cent year on year to Rs13,007 million. PL attributes the weakness to soft commodity prices and genericisation pressure in the global crop-protection market.

Management said the market is showing early signs of demand stabilisation and expects a CSM-led export recovery in H2FY27. Products launched over the past three years contributed 16 per cent to 18 per cent of Q1FY27 revenue. Management plans to launch four to five new CSM molecules in FY27, including its first indigenously discovered insecticide for the domestic and eventual global market.

Domestic Agri-Input and Biologicals Performance

Domestic agri-input distribution revenue was Rs3,481 million, with the branded agchem business up 2 per cent year on year. Biologicals grew 50 per cent, although the core domestic business was affected by severe heat, delayed sowing and high prior-year inventory.

Management noted margin pressure from higher input costs. PIOXANILIPROLE is expected to have an early India launch in FY27, with other geographies expected from the following year.

Pharma Business Scale-up

PI Health Science, the pharma business, reported revenue of Rs542 million, down 25 per cent year on year because of order-book phasing. The business remains in ramp-up mode and has added four marquee customers in the previous 12 months.

PI Health Science has commissioned an Italy-regulator-approved quality-control laboratory and expects one to two product launches.

Management Guidance and Earnings Outlook

Management guided to lower-single-digit FY27 revenue growth and an FY27 tax rate of around 23 per cent to 24 per cent. PL forecasts revenue, EBITDA and PAT compound annual growth rates of about 6 per cent, 5 per cent and negative 1 per cent, respectively, over FY26 to FY28E.

Valuation

PL estimates FY28E EPS of Rs85.6 and values P.I. Industries at 30 times FY28E EPS. At the report CMP of Rs2,483, the stock was trading at 29 times FY28E EPS. The broker's target price is Rs2,569.

Key Risks

• Prolonged external weakness in the agrochemical sector.
• Delayed export recovery.
• Continued pressure related to pyroxasulfone following its patent expiry.
• Domestic weather and inventory disruptions.
• Pharma order-book phasing.